NovaBay details due bills for $0.80 special dividend

Rhea-AI Filing Summary

NovaBay Pharmaceuticals is clarifying how its previously announced one-time special cash dividend of $0.80 per share will be handled in trading on NYSE American. Because the dividend is more than 25% of the company’s share price, NYSE American has advised that NovaBay’s common stock will trade with “due bills” from the September 15, 2025 record date through the close of trading on September 29, 2025, the payment date and last trading day before the September 30, 2025 ex-dividend date.

During this Dividend Right Period, investors who sell NovaBay shares will also transfer the right to receive the $0.80 special dividend to the buyer. Brokers settle these due bill obligations between themselves, and NovaBay states it has no responsibility for the amount or processing of any due bills. The company encourages buyers and sellers of its stock to consult their brokers so they understand how the due bill procedures affect dividend entitlement.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What special dividend did NovaBay Pharmaceuticals (NBY) announce?

NovaBay declared a one-time special cash dividend of $0.80 per share on its common stock, with the dividend scheduled to be paid on September 29, 2025.

What are the key dates for NovaBay (NBY)'s $0.80 special dividend?

Record date: September 15, 2025. Payment date: September 29, 2025. Ex-dividend date: September 30, 2025, the first trading day after the dividend is paid.

What is the Dividend Right Period for NovaBay (NBY) shares?

The Dividend Right Period runs from the September 15, 2025 record date through the close of trading on September 29, 2025, when NovaBay’s shares will trade with due bills representing the right to the special dividend.

What happens if I sell NovaBay (NBY) stock during the Dividend Right Period?

Stockholders who sell NovaBay common stock during the Dividend Right Period will sell their right to the $0.80 special dividend and will not receive the dividend; the buyer will be entitled to it through the due bill mechanism.

What are due bills in connection with NovaBay (NBY)'s special dividend?

Due bills are obligations that assign the right to the special dividend from the seller to the buyer when shares trade during the Dividend Right Period. These obligations are typically settled between brokers.

Is NovaBay responsible for processing due bills for its $0.80 dividend?

No. NovaBay states it has no obligation for the amount or processing of any due bills; those obligations are customarily settled between the brokers for buyers and sellers.

Where can investors find more details about NovaBay (NBY)'s dividend announcement?

Additional details are provided in the company’s press release dated September 18, 2025, which is included as Exhibit 99.1 to the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/18/2025 - 04:33 PM Learn about SEC filing dates

false 0001389545 0001389545 2025-09-18 2025-09-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

NovaBay Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-33678		68-0454536
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2000 Powell Street, Suite 1150, Emeryville, CA 94608

(Address of principal executive offices and zip code)

(510) 899-8800

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☒	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		NBY		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure. 

On September 18, 2025, NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announced that, because the payment of the one-time special cash dividend of $0.80 per share for the Company’s common stock, which is to be paid on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025, represents more than 25% of the price of the Company’s common stock, NYSE American advised the Company that its common stock will trade with “due bills” representing an assignment of the right to receive the special dividend from the record date of September 15, 2025 through the close of trading on NYSE American on September 29, 2025, which is the payment date and the last day of trading before the September 30, 2025 ex-dividend date (this period of time representing the “Dividend Right Period”).

Stockholders who sell their common stock during the Dividend Right Period will be selling their right to the special dividend, and such stockholders will not be entitled to receive the special dividend. Due bills obligate a seller of common stock to deliver the special dividend payable on such common stock to the buyer (i.e., a dividend right). Due bill obligations are customarily settled between the brokers representing the buyers and the sellers of shares. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of the Company’s common stock should consult their brokers before trading to be sure they understand the effect of NYSE American’s due bill procedures.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit
99.1		Press release, dated September 18, 2025, from the Company

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 18, 2025	NovaBay® Pharmaceuticals, Inc.
	By:	/s/ David Lazar
		Name:	David Lazar
		Title:	Chief Executive Officer

2